Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 84677-075

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 84677-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vht 160mg-12.5mg (gsms-sciegen)-p2.jpg (Vht 160mg 12.5mg (gsms Sciegen) P2)

Label for Valsartan and Hydrochlorothiazide Tablets, USP 160 mg/12.5 mg from Golden State Medical Supply, Inc. The film-coated tablet label includes NDC 84677-073-90, quantity of 90 tablets, and directions to keep out of reach of children. Storage conditions and marketing address in Camarillo, CA, are also displayed.*

FDA Label Image

Vht 160mg-25mg (gsms-sciegen)-p2.jpg (Vht 160mg 25mg (gsms Sciegen) P2)

Label for Valsartan and Hydrochlorothiazide Tablets, USP, containing 160 mg of valsartan and 25 mg of hydrochlorothiazide per film-coated tablet. The label shows the strength prominently and indicates a package size of 90 tablets. It includes storage instructions, a barcode, and the labeler GSMS, Incorporated, located in Camarillo, CA.*

FDA Label Image

Vht 320mg-12.5mg (gsms-sciegen)-p2.jpg (Vht 320mg 12.5mg (gsms Sciegen) P2)

Label for Valsartan and Hydrochlorothiazide Tablets, USP 320 mg/12.5 mg. The film-coated tablet packaging shows it contains 90 tablets. The label includes storage instructions, a barcode, and states the product is marketed by GSMS, Incorporated in Camarillo, CA. It also emphasizes keeping medications out of children's reach and mentions dispensing in a tight container.*

FDA Label Image

Vht 320mg-25mg (gsms-sciegen)-p2.jpg (Vht 320mg 25mg (gsms Sciegen) P2)

Label for Valsartan and Hydrochlorothiazide tablets, USP, 320 mg/25 mg strength. The film-coated oral tablets are supplied in a package containing 90 tablets. The label includes storage instructions, a barcode, and the marketer GSMS, Incorporated, Camarillo, CA. The product is prescription-only (Rx Only).*

FDA Label Image

Vht 80mg-12.5mg (gsms-sciegen)-p2.jpg (Vht 80mg 12.5mg (gsms Sciegen) P2)

Label for Valsartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg strength. The film-coated tablets are packaged in a container of 90 tablets. The label includes dosage storage instructions, a barcode, and is marketed by GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

Figure1 (Valsartan01)

A line graph depicting the percentage of patients with systolic blood pressure (SBP) below 140 mmHg, plotted against baseline SBP values ranging from 140 to 180 mmHg. Four treatment groups are shown: Valsartan HCT 320/25 mg (black circles), Valsartan 320 mg (open triangles), Hydrochlorothiazide 25 mg (open squares), and Placebo (crosses). The graph shows higher percentages for Valsartan HCT 320/25 mg across baseline SBP values.*

FDA Label Image

Figure2 (Valsartan02)

A line graph depicting % DBP<90 (diastolic blood pressure below 90 mmHg) versus baseline DBP (mmHg) for four groups: valsartan HCT 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo. Each group is represented by distinct markers and lines showing decreasing % DBP<90 as baseline DBP increases.*

FDA Label Image

Figure3 (Valsartan03)

A line graph comparing the percentage of subjects with systolic blood pressure (SBP) under 130 mmHg against baseline SBP values ranging from 140 to 180 mmHg. The graph plots four groups: valsartan HCT 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo, each represented by different symbols. The y-axis shows the percentage of subjects with SBP below 130 mmHg, while the x-axis shows baseline SBP in mmHg.*

FDA Label Image

Figure4 (Valsartan04)

A line chart depicting the percentage of subjects achieving diastolic blood pressure (DBP) below 80 mmHg versus baseline DBP levels in mmHg. The chart compares four treatments: valsartan HCT 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo, using distinct symbols for each.*

FDA Label Image

Figure5 (Valsartan05)

Chemical structure diagram of valsartan, the active ingredient in the medication valsartan and hydrochlorothiazide. The diagram shows the molecular arrangement and bonds of valsartan's chemical constituents.*

FDA Label Image

Figure6 (Valsartan06)

Chemical structure diagram of the active ingredient valsartan and hydrochlorothiazide showing molecular components including a benzene ring with substituents such as chloride (Cl), sulfonamide group (SO2NH), and other chemical groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.